ATE517183T1 - MONOCLONAL ANTIBODIES AGAINST CD20 - Google Patents

MONOCLONAL ANTIBODIES AGAINST CD20

Info

Publication number
ATE517183T1
ATE517183T1 AT09011119T AT09011119T ATE517183T1 AT E517183 T1 ATE517183 T1 AT E517183T1 AT 09011119 T AT09011119 T AT 09011119T AT 09011119 T AT09011119 T AT 09011119T AT E517183 T1 ATE517183 T1 AT E517183T1
Authority
AT
Austria
Prior art keywords
monoclonal antibody
monoclonal antibodies
antibodies against
antigen
cell
Prior art date
Application number
AT09011119T
Other languages
German (de)
Inventor
Masanori Numazaki
Tetsuo Nakamura
Sadakazu Usuda
Eduardo A Padlan
Original Assignee
Biomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE517183(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomedics Inc filed Critical Biomedics Inc
Application granted granted Critical
Publication of ATE517183T1 publication Critical patent/ATE517183T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Abstract

Disclosed is a monoclonal antibody capable of inducing a specific biological reaction through the binding of the monoclonal antibody to a CD20 antigen on the surface of a cell. A monoclonal antibody having a high binding affinity to an extracellular epitope of a CD20 antigen and also having biological activities including a cell growth inhibitory activity is cloned. The monoclonal antibody is chimerized or humanized to develop a therapeutic agent for a disease in which B cells are involved.
AT09011119T 2005-03-31 2006-03-31 MONOCLONAL ANTIBODIES AGAINST CD20 ATE517183T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005103093 2005-03-31
JP2005378466 2005-12-28

Publications (1)

Publication Number Publication Date
ATE517183T1 true ATE517183T1 (en) 2011-08-15

Family

ID=37073509

Family Applications (2)

Application Number Title Priority Date Filing Date
AT09011119T ATE517183T1 (en) 2005-03-31 2006-03-31 MONOCLONAL ANTIBODIES AGAINST CD20
AT06730873T ATE495248T1 (en) 2005-03-31 2006-03-31 MONOCLONAL ANTI-CD20 ANTIBODY

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06730873T ATE495248T1 (en) 2005-03-31 2006-03-31 MONOCLONAL ANTI-CD20 ANTIBODY

Country Status (18)

Country Link
US (1) US8101179B2 (en)
EP (2) EP2143795B1 (en)
JP (1) JP4813465B2 (en)
KR (1) KR101188117B1 (en)
CN (1) CN101870730A (en)
AT (2) ATE517183T1 (en)
AU (2) AU2006231784B2 (en)
BR (1) BRPI0609543B1 (en)
CA (1) CA2603414C (en)
DE (1) DE602006019565D1 (en)
DK (1) DK2143795T3 (en)
HK (2) HK1138621A1 (en)
IL (2) IL186387A (en)
MX (1) MX2007012197A (en)
PL (1) PL2143795T3 (en)
RU (1) RU2415871C2 (en)
TW (1) TWI381050B (en)
WO (1) WO2006106959A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2096166A1 (en) * 2005-03-31 2009-09-02 Osaka University Method for production of antibody directed against cell membrane surface antigen epitope and assaying method
JPWO2007102200A1 (en) * 2006-03-07 2009-07-23 国立大学法人大阪大学 Anti-CD20 monoclonal antibody
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
AR073295A1 (en) 2008-09-16 2010-10-28 Genentech Inc METHODS TO TREAT PROGRESSIVE MULTIPLE SCLEROSIS. MANUFACTURING ARTICLE.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US8815242B2 (en) 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
IN2012DN01920A (en) 2009-09-03 2015-07-24 Schering Corp
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
BR112012020102A2 (en) 2010-02-10 2016-11-29 Immunogen Inc cd20 antibodies and uses thereof.
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
CA2835489C (en) 2010-05-10 2018-03-06 Chi-Huey Wong Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
JP2013541501A (en) 2010-08-03 2013-11-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Biomarkers for chronic lymphocytic leukemia (CLL)
CN107936121B (en) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use thereof
CN103033621B (en) * 2011-10-09 2016-01-20 嘉和生物药业有限公司 A kind of detection method of anti-CD-20 monoclonal antibody binding activities
CA2858964A1 (en) * 2011-12-13 2013-06-20 Nordic Nanovector As Chimeric therapeutic anti-cd37 antibodie hh1
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
KR102134088B1 (en) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
BR112015026297B1 (en) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc USE OF A TOR KINASE INHIBITOR AND 5-SUBSTITUTED QUINAZOLINONE, PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM, AND KIT
MX2015014596A (en) 2013-04-17 2016-03-03 Signal Pharm Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer.
US9358232B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
WO2014179661A1 (en) 2013-05-03 2014-11-06 Celgene Corporation Methods for treating cancer using combination therapy
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
WO2015035337A1 (en) 2013-09-06 2015-03-12 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
TWI717319B (en) 2014-05-27 2021-02-01 中央研究院 Fucosidase from bacteroides and methods using the same
CN106573971A (en) 2014-05-27 2017-04-19 中央研究院 Anti-CD20 glycoantibodies and uses thereof
CN106661099A (en) 2014-05-27 2017-05-10 中央研究院 Anti-her2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267044A1 (en) 2014-05-28 2016-12-15 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3789766A1 (en) 2015-01-24 2021-03-10 Academia Sinica Novel glycan conjugates and methods of use thereof
IL292708B1 (en) 2015-05-30 2024-04-01 Molecular Templates Inc De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3426693A4 (en) 2016-03-08 2019-11-13 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
EP3487880A1 (en) 2016-07-25 2019-05-29 Biogen MA Inc. Anti-hspa5 (grp78) antibodies and uses thereof
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
JP7046089B2 (en) * 2017-03-09 2022-04-01 マブ ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング Antibodies that specifically bind to human IL-1R7
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
MX2020013428A (en) * 2018-08-21 2021-07-16 Albert Einstein College Of Medicine Monoclonal antibodies against human tim-3.
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111808191A (en) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 Antibody pair for detecting VEGF content in serum and application thereof
WO2022019924A1 (en) * 2020-07-23 2022-01-27 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
JP7057954B2 (en) * 2020-09-03 2022-04-21 国立大学法人大阪大学 Protein-containing liquid formulation with improved storage stability
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
IL308154A (en) 2021-07-30 2023-12-01 Affimed Gmbh Duplexbodies
CA3233696A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
CN114773474B (en) * 2022-05-20 2023-05-16 赛尔托马斯生物科技(成都)有限公司 NK cell preparation method and anticancer application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JP3582965B2 (en) 1996-08-23 2004-10-27 株式会社イムノ・ジャパン Expression vector for mammalian cells
JP2001074737A (en) 1999-09-03 2001-03-23 Asahi Breweries Ltd ANTI-HUMAN IgE MONOCHLONAL ANTIBODY
ES2358977T3 (en) 2001-03-15 2011-05-17 Neogenix Oncology, Inc. THERAPY WITH MONOCLONAL ANTIBODIES FOR CANCER CANCER.
CN100522999C (en) 2002-02-14 2009-08-05 免疫医疗公司 Anti-CD20 antibodies and fusion proteins thereof and methods of use
NZ543960A (en) 2003-05-09 2008-11-28 Univ Duke CD20-specific antibodies and methods of employing same
CA2544368C (en) * 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
JPWO2007102200A1 (en) * 2006-03-07 2009-07-23 国立大学法人大阪大学 Anti-CD20 monoclonal antibody

Also Published As

Publication number Publication date
DE602006019565D1 (en) 2011-02-24
EP2143795A3 (en) 2010-02-24
BRPI0609543B1 (en) 2021-11-09
MX2007012197A (en) 2007-11-21
AU2006231784A1 (en) 2006-10-12
JPWO2006106959A1 (en) 2008-09-18
RU2007140257A (en) 2009-05-10
EP1865058B1 (en) 2011-01-12
CA2603414C (en) 2012-09-18
JP4813465B2 (en) 2011-11-09
IL186387A (en) 2011-03-31
EP2143795A2 (en) 2010-01-13
BRPI0609543A2 (en) 2011-10-18
WO2006106959A1 (en) 2006-10-12
EP1865058A1 (en) 2007-12-12
US20090197330A1 (en) 2009-08-06
TWI381050B (en) 2013-01-01
ATE495248T1 (en) 2011-01-15
IL186387A0 (en) 2008-01-20
KR20070116175A (en) 2007-12-06
HK1138621A1 (en) 2010-08-27
US8101179B2 (en) 2012-01-24
TW200714711A (en) 2007-04-16
DK2143795T3 (en) 2011-09-19
CA2603414A1 (en) 2006-10-12
PL2143795T3 (en) 2011-12-30
HK1111728A1 (en) 2008-08-15
AU2010214745A1 (en) 2010-09-23
EP1865058A4 (en) 2009-03-25
CN101870730A (en) 2010-10-27
AU2006231784B2 (en) 2010-10-14
AU2010214745B2 (en) 2011-12-15
EP2143795B1 (en) 2011-07-20
RU2415871C2 (en) 2011-04-10
IL206783A (en) 2012-03-29
KR101188117B1 (en) 2012-10-09

Similar Documents

Publication Publication Date Title
ATE517183T1 (en) MONOCLONAL ANTIBODIES AGAINST CD20
MA29595B1 (en) HUMANIZED ANTI-CD40 ANTIBODIES AND METHODS OF USE
RU2406730C2 (en) Humanised monoclonal ahti-cd20-antibody
ATE477276T1 (en) INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES
SI1810026T1 (en) B7-h1 and pd-1 in treatment of renal cell carcinoma
ATE505544T1 (en) MONOCLONAL ANTIBODIES AND SINGLE CHAIN ANTIBODIES FRAGMENTS AGAINST CELL SURFACE PROSTATE SPECIFIC MEMBRANE ANTIGEN
AR052284A1 (en) VARIATIONS OF AN ANTIBODY AND USES OF THE SAME
NO20071436L (en) Humanized Anti-5T4 Antibodies and Anti-5T4 Antibody / Calicheamicin Conjugates
WO2005012493A3 (en) Anti-cd19 antibodies
BRPI0811526A2 (en) use of a chimeric, humanized or human monoclonal antibody that binds il-5r, isolated anti-il-5r antibody, and isolated il-5r alpha epitope
DK1565489T3 (en) Internalizing antibodies specific for the RAAG10 cell surface target
DK2066349T3 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND USE THEREOF IN TREATMENT OF TUMORS, TRANSPLANTATION AND AUTOIMMUNE DISEASES
WO2006099141A3 (en) Anti-mesothelin antibodies
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
DK1684805T3 (en) Use of antagonist anti-CD40 monoclonal antibodies to treat multiple myeloma
CR20120587A (en) MOLECULES OF UNION TO THE ANTIGEN FIXED BY EGFR, VECTORS THAT CODE THEM AND USE OF THE SAME
DK1641828T3 (en) Anti-HGF-R antibodies and their use
ATE549358T1 (en) NEW ANTI-PLGF ANTIBODY
EA200700083A1 (en) ANTIBODIES DIRECTED AGAINST BETA AMYLOID PEPTIDE, AND METHODS OF THEIR APPLICATION
DK2070948T3 (en) Human Anti-CD4 antibody with immunosuppressive properties
WO2007087289A3 (en) Anti-fcrn antibodies for treatement of auto/allo immune conditions
UA94211C2 (en) Isolated fully human monoclonal anti-cd3 antibody
WO2008146165A3 (en) Kit of parts for the treatment of cancer or infectious diseases
NZ595863A (en) Antibodies to egfl7 and methods for their use
ATE517340T1 (en) SETS OF DIGITAL ANTIBODIES DIRECTED AGAINST SHORT EPITOPES AND METHODS USING THEM

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2143795

Country of ref document: EP